CO2022014520A2 - Anticuerpos anti-flt3 y composiciones - Google Patents

Anticuerpos anti-flt3 y composiciones

Info

Publication number
CO2022014520A2
CO2022014520A2 CONC2022/0014520A CO2022014520A CO2022014520A2 CO 2022014520 A2 CO2022014520 A2 CO 2022014520A2 CO 2022014520 A CO2022014520 A CO 2022014520A CO 2022014520 A2 CO2022014520 A2 CO 2022014520A2
Authority
CO
Colombia
Prior art keywords
compositions
flt3 antibodies
flt3
antibodies
patient
Prior art date
Application number
CONC2022/0014520A
Other languages
English (en)
Spanish (es)
Inventor
Trine Lindsted
Mikkel Wandahl Pedersen
Randi Westh Hansen
Eva Maria Carlsen Melander
Matteo Riva
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CO2022014520A2 publication Critical patent/CO2022014520A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2022/0014520A 2020-04-14 2022-10-13 Anticuerpos anti-flt3 y composiciones CO2022014520A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063009578P 2020-04-14 2020-04-14
PCT/EP2021/059646 WO2021209495A1 (en) 2020-04-14 2021-04-14 Anti-flt3 antibodies and compositions

Publications (1)

Publication Number Publication Date
CO2022014520A2 true CO2022014520A2 (es) 2022-11-08

Family

ID=75530015

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014520A CO2022014520A2 (es) 2020-04-14 2022-10-13 Anticuerpos anti-flt3 y composiciones

Country Status (17)

Country Link
US (2) US12252539B2 (cg-RX-API-DMAC7.html)
EP (1) EP4136114A1 (cg-RX-API-DMAC7.html)
JP (1) JP7679399B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220167331A (cg-RX-API-DMAC7.html)
CN (1) CN115715297A (cg-RX-API-DMAC7.html)
AU (1) AU2021255884A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020683A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180188A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002833A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014520A2 (cg-RX-API-DMAC7.html)
IL (1) IL297269A (cg-RX-API-DMAC7.html)
MX (1) MX2022012919A (cg-RX-API-DMAC7.html)
PE (1) PE20230075A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552710A1 (cg-RX-API-DMAC7.html)
TW (1) TWI910146B (cg-RX-API-DMAC7.html)
WO (1) WO2021209495A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211267B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230075A1 (es) * 2020-04-14 2023-01-11 Servier Lab Anticuerpos anti-flt3 y composiciones
WO2024108163A2 (en) * 2022-11-18 2024-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd135 polypeptides
US20260217851A1 (en) * 2022-12-22 2026-07-30 The Medical College Of Wisconsin, Inc. Compositions that Target CD138 and CD3 and Methods of Making and Using the Same
CN122055383A (zh) * 2023-07-12 2026-05-15 费诺米人工智能公司 抗cthrc1 t细胞衔接体及其使用方法
CN118924724B (zh) * 2024-07-29 2025-11-04 湖南大学 一种用于治疗神经母细胞瘤的药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1186301B1 (en) 1993-09-08 2006-08-16 Imclone Systems, Inc. Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
WO2002066044A2 (en) 2000-10-24 2002-08-29 Immunex Corporation Method for dendritic cells based immunotherapy of tumors using combination therapy
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
ES2573642T3 (es) 2009-12-23 2016-06-09 Synimmune Gmbh Anticuerpos anti-FLT3 y métodos de usar los mismos
KR20240056629A (ko) 2014-09-28 2024-04-30 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Flt3及cd3抗體構築體
EP3559038B1 (en) 2016-12-21 2022-12-14 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
PE20241587A1 (es) 2017-06-02 2024-08-01 Pfizer Receptores de antigenos quimericos que se dirigen a flt3
JP7234142B2 (ja) 2017-06-02 2023-03-07 ファイザー・インク Flt3に特異的な抗体およびその使用
EP3850010A1 (en) * 2018-09-11 2021-07-21 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved anti-flt3 antigen binding proteins
EP3902836B1 (en) * 2018-12-18 2026-03-25 Boehringer Ingelheim IO Canada Inc. Flt3 agonist antibodies and uses thereof
PE20230075A1 (es) * 2020-04-14 2023-01-11 Servier Lab Anticuerpos anti-flt3 y composiciones

Also Published As

Publication number Publication date
EP4136114A1 (en) 2023-02-22
KR20220167331A (ko) 2022-12-20
US12252539B2 (en) 2025-03-18
US20210317216A1 (en) 2021-10-14
JP7679399B2 (ja) 2025-05-19
ZA202211267B (en) 2026-05-27
TW202200620A (zh) 2022-01-01
CA3180188A1 (en) 2021-10-21
WO2021209495A1 (en) 2021-10-21
MX2022012919A (es) 2022-11-16
CL2022002833A1 (es) 2023-06-09
PE20230075A1 (es) 2023-01-11
TWI910146B (zh) 2026-01-01
US20250179195A1 (en) 2025-06-05
BR112022020683A2 (pt) 2022-11-29
IL297269A (en) 2022-12-01
CN115715297A (zh) 2023-02-24
AU2021255884A1 (en) 2022-11-17
JP2023522630A (ja) 2023-05-31
PH12022552710A1 (en) 2024-03-25

Similar Documents

Publication Publication Date Title
CL2022002833A1 (es) Anticuerpos anti-flt3 y composiciones
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
MX2022007678A (es) Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
ECSP22083269A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CL2019002850A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3.
ECSP21052193A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
CL2020003249A1 (es) Antagonista gremlin-1 para la prevención y tratamiento del cáncer
CO2020005887A2 (es) Compuestos policíclicos como inhibidores alostéricos de shp2
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX2021007768A (es) Anticuerpos anti-ctla4 y metodos de uso de los mismos.
CL2016000538A1 (es) Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos
CL2023003562A1 (es) Anticuerpos y composiciones anti-nkg2a
CR20150088A (es) Anticuerpos anti-notch1 nrr
CL2021003228A1 (es) Compuestos tricíclicos y su uso
ECSP21052194A (es) Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
MX2021002301A (es) Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
AR121839A1 (es) Anticuerpos anti-flt3 y composiciones
MX2024014771A (es) Terapia combinada